Navigation Links
China Pharma Holdings, Inc. Reports Third Quarter 2008 Financial Results and Corporate Updates

HAIKOU CITY, China, Nov. 7 /Xinhua-PRNewswire-FirstCall/ -- China Pharma Holdings, Inc. ("China Pharma") (OTC Bulletin Board: CPHI), which develops, manufactures, and markets generic and branded speciality pharmaceutical products in China, today announced financial results for the quarter ended September 30, 2008.

Financial Highlights

-- 3Q08 Revenue of $12.6 Million, up 52.0% Year-over-Year

-- $35.6 Million Revenue for nine months ended September 30, up 47.76%

versus same period in 2007

-- 3Q08 Net Income up 37.8% Year-over-Year; up 42.05% in nine months ended

September 30 versus same period in 2007

-- 3Q08 Diluted EPS $0.10 versus 3Q07 Diluted EPS $0.08

-- Diluted EPS $0.32 versus Diluted EPS $0.24 for nine months ended

September 30, 2008 and 2007, respectively

-- 3Q08 Sales of PuSenOK(TM), China's first and only generic version of

Aleve-D(R), Up 124.2% Year-over-Year

Recent and Upcoming Events

-- Clinical Trials of Novel Antibiotic Combination Approved by SFDA and


-- AMEX Listing Plans Underway

-- Two-Week U.S. Tour in November 2008 to Present at Conferences and Meet


Revenue for the third quarter of 2008 increased 52.05% to $12.61 million, compared to $8.29 million in the same period of 2007 and above management's prior guidance for revenue growth of 40%-45%. The increase reflected the expansion of marketing and promotional activities aimed at increasing the sales of existing products, in addition to the Company's increase in pharmaceutical market share from the introduction of new products. Top contributors to the increase in revenue were the Company's branded product PuSenOK(TM), the first and only generic version of Aleve-D(R) available in China; Buflomedil, a treatment for peripheral blood vessel diseases; Roxithromycin dispersible tablet, a macrolide antibiotic; and Bumetanide, a diuretic approved by the SFDA in January 2008 for the treatment of edema caused by heart disease and hypertension. The Company continues to focus on expanding its capacity and distribution networks to support the development, manufacturing and sales of additional products.

Operating expenses in the third quarter of 2008 totaled $1.42 million, up 87.89% from approximately $0.76 million in the comparable period of 2007. The main reason was $0.46 million in Allowance for Bad Debt for this period, because in the same period last year, a substantial amount of aged receivables was collected, making that period's Allowance for Bad Debt, negative $0.17 million. Operating income in the third quarter of 2008 was approximately $4.7 million, an increase of 50.29% from approximately $3.1 million in the same period of 2007, while operating margin was approximately 37.23%, compared to 37.66% in the third quarter of 2007.

Gross profit in the third quarter of 2008 was approximately $6.12 million, up 57.62% compared to approximately $3.88 million in the third quarter of 2007. Gross margin was approximately 48.5%, higher than 46.79% in the prior year's period, and above the pharmaceutical industry's average of 34.2%.

Net income for the third quarter of 2008 rose 37.82% to approximately $4.25 million, or $0.10 per basic and diluted share, compared to $3.08 million, or $0.08 per basic and diluted share, in the same period a year ago. Diluted share count in the third quarter of 2008 was approximately 42.3 million, compared to approximately 37.2 million in the third quarter of 2007.

President and CEO, Ms. Zhilin Li, commented, "We are confident that our continued strong revenue growth for the third quarter of 2008 is a reflection of our focus on the largest segments of China's pharmaceutical market, in disease areas of high incidence and high mortality. Our rapid growth is supported by the ongoing delivery of new products, product technology, and branding. We are competitive within China's highly fragmented pharmaceutical market due to our high margin and low cost business model, which is supported by our scalable manufacturing infrastructure and diverse product portfolio based on market demand. Our near-term strategy is to maintain rapid growth by investing in marketing and promotional activities to increase sales and market share, expanding distribution, and developing competitive new products."

Recent and Upcoming Milestones

Clinical Trials of Novel Antibiotic Combination Approved by SFDA and Initiated

In November 2008, the Company initiated clinical trials of its novel antibiotic combination formula after the SFDA completed its technical analyses and cleared the product for clinical trials. The novel antibiotic combination is a third generation Cephalosporin antibiotic formulated with a bacterial- enzyme inhibitor for the treatment of infections. The inclusion of a bacterial-enzyme inhibitor gives it the potential to address antibiotic- resistant infections, which are on the rise in China.

AMEX Listing Plans Underway

The Company is confident that it meets AMEX listing requirements pending compliance with minimum bid price rules. During senior management's trip to the U.S., the team will continue to discuss listing preparations with specialists and advisors.

Two-Week U.S. Tour in November 2008 to Present at Conferences and Meet Investors

Ms. Zhilin Li, President and CEO, will visit the U.S. for the first time with senior management to meet investors and participate in two investor conferences. The U.S. tour will begin on November 10, 2008 in New York City, where management will present at Rodman and Renshaw's Annual Global Investment Conference. Management will visit investors in several other cities, including Los Angeles and San Francisco. The tour will conclude on November 21, 2008 in Las Vegas, Nevada, where management will present at Roth Capital's "China Comes to Vegas" conference. Management is available during each conference and in each city for one-on-one meetings.

"I am looking forward to meeting with our current and potential investors, during my first visit to the U.S.," added Ms. Li. "I am eager to discuss our recent accomplishments, particularly those we have highlighted today. The success of PuSenOK as the only generic Aleve-D in China has significantly increased the brand recognition of China Pharma Holdings, which we expect to benefit our current and future products on the market. We are also actively advancing our research and development pipeline, as demonstrated by the recent initiation of clinical trials for our novel antibiotic combination. The company's sustained development strategy is to focus on specific markets and strengthen our competitive advantages through the further development of products technology and brand creation, and by deepening the penetration of our distribution network while taking full advantage of growth opportunities emerging from China's recent healthcare reforms."

Conference Call Details

The Company will hold a conference call today at 10:00 a.m. ET. To participate in the conference call, please dial 1-800-591-6945 (USA) or +1- 617-614-4911 (International), Conference Passcode 57906502. In addition, a dial-up replay of the conference call will be available beginning November 7, 2008 at 12:00 p.m. ET and ending on November 14, 2008. The replay telephone number is 1-888-286-8010 (USA) or +1-617-801-6888 (International), Conference Passcode: 19590263.

This conference call will be broadcast live over the Internet and can be accessed by clicking this link: . A replay will also be available shortly after the call on China Pharma's website .

About China Pharma Holdings, Inc.

China Pharma Holdings, Inc. is a specialty pharmaceutical company with rapidly growing profit that develops, manufactures, and markets treatments for a wide range of high incidence and high mortality conditions in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective, high margin business model is driven by market demand and supported by eight scalable GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding distribution network across 30 provinces, municipalities and autonomous regions. The Company is registered in Delaware, USA. Hainan Helpson Bio- pharmaceutical Co., Ltd (Helpson), located in Haikou City, Hainan Province, China, is a wholly owned subsidiary of China Pharma Holdings, Inc. For more information about China Pharma Holdings, Inc., please visit .

September 30, December 31,

2008 2007



Current Assets:

Cash and cash equivalents $5,838,678 $1,830,335

Trade accounts receivable, less

allowance for doubtful accounts

of $4,124,577 and

$2,440,852, respectively 31,670,231 18,572,976

Other receivables, less allowance for

Doubtful accounts of $98,151

and $43,908,respectively 189,794 413,596

Advances to suppliers 2,276,440 2,757,320

Inventory 14,542,799 14,448,771

Total Current Assets 54,517,942 38,022,998

Non-current Assets:

Property and equipment, net of

accumulated depreciation of

$1,350,913 and $1,003,802,

respectively 2,619,965 2,625,216

Intangible assets, net of accumulated

amortization of $465,132 and

$221,715, respectively 2,432,253 2,063,252

Advances for purchases of

intangible assets 6,840,631 807,345

Deferred tax assets 413,890 187,509

Total Non-current Assets 12,306,739 5,683,322

TOTAL ASSETS $66,824,681 $43,706,320


Current Liabilities:

Trade accounts payable $505,704 $297,299

Accrued expenses 47,450 261,301

Accrued taxes payable 946,948 311,009

Other payables 130,652 86,161

Advances from customers 674,135 261,583

Short-term notes payable -- 2,693,428

Total Current Liabilities 2,304,889 3,910,781

Research and development commitments 36,381 34,181

Total Liabilities 2,341,270 3,944,962

Stockholders' Equity:

Common stock, $0.001 par value,

60,000,000 shares authorized,

42,278,938 and 37,278,938 shares

issued and outstanding, respectively 42,279 37,279

Additional paid-in capital 21,062,586 11,678,606

Foreign currency translation

adjustment 5,693,059 2,839,304

Retained earnings 37,685,487 25,206,169

Total Stockholders' Equity 64,483,411 39,761,358



For the three months For the nine months

ended September 30, ended September 30,

2008 2007 2008 2007

Revenue $12,610,642 $8,293,497 $35,606,490 $24,097,521

Cost of revenue 6,494,266 4,413,052 17,730,026 13,018,566

Gross profit 6,116,376 3,880,445 17,876,464 11,078,955

Operating expenses:

Selling expenses 529,432 591,193 1,323,854 896,128

General and

administrative 427,399 328,743 1,226,888 927,162

Research and

development 5,581 5,941 42,807 5,942

Bad debt expense, net

of recoveries 459,500 (169,095) 1,539,313 910,718

Total operating

expenses 1,421,912 756,782 4,132,862 2,739,950

Income from operations 4,694,464 3,123,663 13,743,602 8,339,005

Non-operating income


Interest income 26,224 4,400 31,259 29,808

Interest expense (34,629) (50,857) (130,342) (166,698)

Other (expense) income (9,588) 7,549 (87,038) 582,827

Total non-operating

income (expense) (17,993) (38,908) (186,121) 445,937

Income before taxes 4,676,471 3,084,755 13,557,481 8,784,942

Income tax expense 424,993 -- 1,078,163 --

Net income $4,251,478 $3,084,755 $12,479,318 $8,784,942

Comprehensive income --

foreign currency


adjustments 133,713 570,646 2,853,755 1,222,329

Comprehensive income $4,385,191 $3,655,401 $15,333,073 $10,007,271

Basic and Diluted

Earnings Per Share $0.10 $0.08 $0.32 $0.24

Basic and Diluted

Weighted Average

Shares Outstanding 42,278,938 37,228,938 39,523,464 36,935,208 CHINA PHARMA HOLDINGS, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)

For the nine months ended

September 30,

2008 2007

Cash Flows from Operating Activities: (Restated)

Net income $12,479,318 $8,784,942

Depreciation and amortization 505,595 322,098

Compensation paid with warrants 120,042 --

Gain on sale of intangibles -- (572,446)

Changes in assets and liabilities:

Trade accounts receivable (11,610,177) (4,440,513)

Other receivables 246,329 223,329

Advances to suppliers 651,833 (2,504,684)

Inventory 855,485 (2,965,836)

Deferred tax assets (209,434) --

Deferred offering costs -- 60,487

Trade accounts payable 184,627 279,420

Accrued expenses (138,021) 83,034

Accrued taxes payable 602,480 --

Other payables (48,535) (134,647)

Advances from customers 386,922 47,448

Net Cash from Operating Activities 4,026,464 (817,368)

Cash Flows from Investing Activities:

Purchase of property and equipment (125,753) (77,313)

Purchase of intangible assets (428,641) (1,993,288)

Advances for purchases of intangibles (5,856,412) --

Net Cash from Investing Activities (6,410,806) (2,070,601)

Cash Flows from Financing Activities:

Proceeds from sale of common stock

and warrants 9,268,938 3,797,183

Payments of short term notes payable (2,814,744) --

Net Cash Proceeds from Financing

Activities 6,454,194 3,797,183

Effect of Exchange Rate Changes on

Cash (61,509) 149,995

Net Change in Cash 4,008,343 1,059,209

Cash and Cash Equivalents at

Beginning of Period 1,830,335 656,441

Cash and Cash Equivalents at End of

Period $5,838,678 $1,715,650

Supplemental Cash Flow Disclosure:

Cash paid for interest $130,342 $115,841

Cash paid for income taxes 1,289,596 --

Safe Harbor Statement

Certain statements in this press release and oral statements made by China Pharma on its conference call in relation to this release, constitute forward- looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as unanticipated changes in product demand, increased competition, failure to obtain or maintain intellectual property protection, downturns in the Chinese economy, uncompetitive levels of research and development, failure to obtain regulatory approvals, and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.

For further information, please contact:

China Pharma Holdings, Inc.

Diana Huang

Tel: +86-898-6681-1730


The Ruth Group

Sara Ephraim

Tel: +1-646-536-7002


SOURCE China Pharma Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. China Pharma Holdings, Inc. to Host Third Quarter 2008 Earnings Conference Call at 10 a.m. EST Friday November 7, 2008
2. TomoTherapy Completes Acquisition of Linear Accelerator Manufacturer in China
3. China Nepstar Chain Drugstore to Announce Third Quarter 2008 Financial Results on November 26
4. China-Biotics, Inc. Announces Conference Call to Discuss Second Quarter 2009 Financial Results
5. China Sky One Medical, Inc. Obtains Production Approval for Two New Drugs
6. China Pharma Holdings, Inc. to Initiate Clinical Trials For New Antibiotic Combination
7. China Medical Technologies to Attend Credit Suisse Asian Healthcare Conference
8. China Sky One Medical, Inc. Acquires Drug to Treat Breast Lesions
9. Simcere Pharmaceutical Group to Participate in Goldman Sachs China Investment Frontier Conference 2008
10. China Sky One Medical, Inc. Receives Tax Refund
11. Mindray Medical to Exhibit New Products at 60th China International Medical Equipment Fair
Post Your Comments:
(Date:12/1/2015)... Wilmington, Delaware (PRWEB) , ... December 01, 2015 ... ... award winner at the 7th Annual 2015 Golden Bridge Business Awards under the ... is a zero capex web based sample management software that ...
(Date:12/1/2015)... ... 01, 2015 , ... The importance of volumetric breast density ... of numerous abstracts accepted for presentation here, at the 101st Annual Radiology Society ... the use of Volpara Solutions’ quantitative breast imaging software tools for providing breast ...
(Date:12/1/2015)... CA (PRWEB) , ... December 01, 2015 , ... ... Health Center of Excellence (BHCOE) today announced that the organization has awarded Education ... San Francisco, with a Distinguished Award. The award celebrates exceptional special needs providers ...
(Date:12/1/2015)... ... December 01, 2015 , ... TCS ... care management and population health arenas, is pleased to announce that VIP Care ... services, has successfully implemented the ACUITY Complete Care™ Management to back their collaborative ...
(Date:12/1/2015)... ... December 01, 2015 , ... With FCPX Overlay: Grit , users can ... customization, the possibilities are truly endless, all with a click of a mouse. Each ... flip, horizontal flip, depth of field and more, all within Final Cut Pro X. ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... , December 1, 2015 ... market research report "Nucleic Acid Labeling Market by Product ... Translation, Random Primer, In Vitro Transcription, Reverse Transcription, End ... by MarketsandMarkets, The global market is expected to reach ... in 2015, growing at a CAGR of 8.65%. ...
(Date:12/1/2015)... 01, 2015 ... "Veterinary Equipment and Disposables Market by product, by ... to their offering. --> ) ... Equipment and Disposables Market by product, by Animal ... their offering. --> Research and Markets ...
(Date:12/1/2015)... 1, 2015  Today, AmerisourceBergen, a ... CareFront, a first-of-its-kind population health management program focused ... Designed to be built into existing employer benefit ... resources for their care and explains how to ... tools to help patients understand their treatment options ...
Breaking Medicine Technology: